Progenics Pharmaceuticals Inc.  (PGNX) Trade Now »     Rate PGNX  -  Discuss PGNX  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

PGNX: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA Calendar Updates: MELA, PGNX, VPHM, WYE PGNX

73%

-32.78% in 98 days <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 288 entries as of 8/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage cli... Continue reading »

FDA Calendar Updates: MITI, KERX, GSK, DYAX, ARNA, PGNX PGNX

73%

+5.99% in 58 days (closed on 08/05/09) <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-s... Continue reading »

From the Blogosphere

Analyst downgrades: Concur Tech, Groupe Danone, General Motors

Filed under: Analyst reports, Analyst upgrades and downgrades, General Motors (GM), UAL Corp (UAUA) MOST NOTEWORTHY: Concur Tech, Groupe Danone and General Motors were today's noteworthy downgrades: <> Piper downgraded shares of Concur Tech (NASDAQ: CNQR) to Neutral from Buy after transferring analyst coverage, as they believe potential upside to estimates is priced into shares while competitive concerns from American Express (NYSE: AXP) are not. <>Morgan Stanley downgraded shares of Groupe Danone (OTC: GDNNY) to Equal Weight from Overweight to reflect reduced visibility in the company's... Continue reading »

Monday's Upgrades and Downgrades

2 %

<> Upgrades Wright Medical (WMGI)- Leerink Swann Mkt Perform » Outperform Axsys Technologies (AXYS)- Boenning & Scattergood Market Perform » Market Outperform Trimble Navigation (TRMB)- Piper Jaffray Neutral » Buy Emulex (ELX)- Morgan Keegan Mkt Perform » Outperform Synovus (SNV)- Bernstein Mkt Perform » Outperform Health Management (HMA)- Credit Suisse Neutral » Outperform Tenet Healthcare (THC)- Credit Suisse Neutral » Outperform Northrop Grumman (NOC)- Cowen & Co Neutral » Outperform Sohu.com (SOHU)- Citigroup Hold » Buy Progenics Pharm (PGNX)- Ci... Continue reading »

Monday's Upgrades and Downgrades

<> Upgrades Wright Medical (WMGI)- Leerink Swann Mkt Perform » Outperform Axsys Technologies (AXYS)- Boenning & Scattergood Market Perform » Market Outperform Trimble Navigation (TRMB)- Piper Jaffray Neutral » Buy Emulex (ELX)- Morgan Keegan Mkt Perform » Outperform Synovus (SNV)- Bernstein Mkt Perform » Outperform Health Management (HMA)- Credit Suisse Neutral » Outperform Tenet Healthcare (THC)- Credit Suisse Neutral » Outperform Northrop Grumman (NOC)- Cowen & Co Neutral » Outperform Sohu.com (SOHU)- Citigroup Hold » Buy Progenics Pharm (PGNX)- Ci... Continue reading »

Pre-Open Movers 2/25:Progenics Pharma (PGNX) Jumps On FDA Approval, Netgear (NTGR) Down on Results

<>StreetInsider.com Pre-Open Movers: Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) 23% HIGHER; Progenics and Wyeth (NYSE: WYE) announced that the FDA has approved RELISTOR subcutaneous injection for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. ISIS Pharmaceuticals Inc. (Nasdaq: ISIS) 23% LOWER; The FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for ... Continue reading »

Analyst upgrades: NOC, PFWD and CLS

Filed under: Analyst reports, Analyst upgrades and downgrades, Wal-Mart (WMT), Wendy's Intl (WEN), Northrop Grumman (NOC) MOST NOTEWORTHY: Northrop Grumman, Phase Forward and Celestica were today's noteworthy upgrades: <> Cowen upgraded Northrop Grumman (NYSE: NOC) to Outperform from Neutral following the Q1 report based on accelerating growth. Shares were also upgraded at JP Morgan to Overweight from Neutral. Friedman Billings upgraded Phase Forward (NASDAQ: PFWD) to Outperform from Market Perform following the solid Q1 report and views guidance as beatable. <>CIBC raised Celestica (N... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.